Bispecific Antibodies Latch Onto Advances – Module 1

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (1 of 5 Modules)

This activity provides an overview of data for new and emerging T-cell directed bispecific antibodies in the management of hematologic malignancies, with a focus on multiple myeloma.

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze available data on bispecific antibodies for the treatment of multiple myeloma

Activity Faculty

Saad Z. Usmani, MD, MBA, FACP

Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Featured RMEI CE Activities – Earn CE Credit(s)

A Non-CME Educational Program during the 2025 AAAAI/WAO Joint Congress: Expert Panel Discussion Featuring a Patient

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

1.5 CE Credit(s)

Rapid Recognition and Management of T-Cell Therapy-Related Toxicities in B-Cell Lymphomas: Crucial Updates for the Emergency Department

1.0 CE Credit(s)

Privacy | Terms of Use